EUVIMEDEUVIMED entdecken
Crossref

Cladribine, low-dose cytarabine, and venetoclax in newly diagnosed and relapsed/refractory acute myeloid leukemia: A global perspective

Iman Abou Dalle, Abdallah Yassine, Ali Awada, Zaher Chakhachiro, Rami Mahfouz, Nour Moukalled, Jean El Cheikh, Ali Bazarbachi

Current Research in Translational Medicine · 2026-04 · 74 (2) · 103576

DOI: 10.1016/j.retram.2026.103576 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Research in Translational Medicine, 2026-04. Verfasst von Iman Abou Dalle und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Hematology-Oncology Division, American University of Beirut Medical Center, Beirut, Lebanon. Electronic address: ia4…. Hauptthemen laut MEDLINE: Sulfonamides, Bridged Bicyclo Compounds, Heterocyclic, Leukemia, Myeloid, Acute, Cladribine. Die Arbeit nennt 24 Literaturangaben. Gefördert von: American University of Beirut.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The combination of cladribine (CLAD), low-dose cytarabine (LDAC), and venetoclax (CLAD-LDAC-venetoclax) has demonstrated promising efficacy in acute myeloid leukemia (AML) but remains underutilized globally. Since 2020, this regimen has been implemented at the American University of Beirut Medical Center (AUBMC) for patients ineligible for intensive chemotherapy. PATIENTS AND METHODS This study evaluates its efficacy and safety in newly diagnosed and relapsed/refractory (R/R) AML. We retrospectively analyzed consecutive AML patients treated with CLAD-LDAC-venetoclax between January 2020 and September 2024. Treatment consisted of cladribine (5 mg/m²/day, 5 days), LDAC (20 mg subcutaneously twice daily, 10 days), and venetoclax (100 mg daily with azole antifungal co-administration). Outcomes are overall response rate (ORR), including complete remission (CR), and CR with incomplete hematologic recovery (CRi), event-free survival (EFS), overall survival (OS), and safety. RESULTS Among 19 frontline patients (median age: 67 years), the ORR was 88% (CR/CRi: 76%/12%), with 47% undergoing allogeneic hematopoietic cell transplantation (allo-HCT). Median EFS was 13.4 months, OS was 35.3 months, and 2-year OS was 58%. In 14 R/R AML patients (all venetoclax-pretreated), ORR was 57% (CR/CRi: 29%/21%), with a median EFS of 2 months and OS of 5.2 months. In both cohorts, infection rates were increased, especially in secondary AML. CONCLUSION CLAD-LDAC-venetoclax was highly effective in newly diagnosed AML, but had limited response durability in the R/R setting, particularly post-venetoclax exposure. These findings support its role as an induction strategy for unfit patients and highlight the need for novel salvage approaches in R/R AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SulfonamidesBridged Bicyclo Compounds, HeterocyclicLeukemia, Myeloid, AcuteCladribineCytarabineAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleAgedRetrospective StudiesMiddle AgedMaleAdultRemission InductionRecurrenceNeoplasm Recurrence, LocalAged, 80 and overSalvage Therapy

Stichwörter der Autor:innen

AMLCladribineNucleoside analogRelapsed and refractoryVenetoclax

Substanzen

SulfonamidesBridged Bicyclo Compounds, HeterocyclicvenetoclaxCladribineCytarabine

Autor:innen und Institutionen

  • Department of Internal Medicine, Hematology-Oncology Division, American University of Beirut Medical Center, Beirut, Lebanon. Electronic address: ia41@aub.edu.lb.
  • Department of Internal Medicine, Hematology-Oncology Division, American University of Beirut Medical Center, Beirut, Lebanon.
  • Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut, Lebanon.

Förderung

  • American University of Beirut

Zitieren

APA

Abou Dalle, I., Yassine, A., Awada, A., Chakhachiro, Z., Mahfouz, R., Moukalled, N., El Cheikh, J., & Bazarbachi, A. (2026). Cladribine, low-dose cytarabine, and venetoclax in newly diagnosed and relapsed/refractory acute myeloid leukemia: A global perspective. Current Research in Translational Medicine, 74(2), 103576. https://doi.org/10.1016/j.retram.2026.103576

Vancouver

Abou Dalle I, Yassine A, Awada A, Chakhachiro Z, Mahfouz R, Moukalled N, et al. Cladribine, low-dose cytarabine, and venetoclax in newly diagnosed and relapsed/refractory acute myeloid leukemia: A global perspective. Current Research in Translational Medicine. 2026;74(2):103576. doi:10.1016/j.retram.2026.103576

BibTeX
@article{AbouDalle2026,
  author = {Abou Dalle, Iman and Yassine, Abdallah and Awada, Ali and Chakhachiro, Zaher and Mahfouz, Rami and Moukalled, Nour and El Cheikh, Jean and Bazarbachi, Ali},
  title = {Cladribine, low-dose cytarabine, and venetoclax in newly diagnosed and relapsed/refractory acute myeloid leukemia: A global perspective},
  journal = {Current Research in Translational Medicine},
  year = {2026},
  volume = {74},
  number = {2},
  pages = {103576},
  doi = {10.1016/j.retram.2026.103576}
}
Kostenlos starten →